Shanghai Invests RMB 120 Million To Boost Biopharma Commercialization
This article was originally published in PharmAsia News
Executive Summary
Shanghai has designated nine key investment areas to boost high-tech industrialization, with the biopharma industry the first to receive funding. The municipal government will allocate a total of RMB 120 million ($17.5 million) to help biopharmaceutical projects and an individual project can receive up to one-tenth of its entire investment. Shanghai Municipality's Science and Technology Commission has published guidelines for fund application. The circular welcomes enterprises in the city that are developing biopharmaceutical products, pharmaceutical chemicals, modernized TCM, medical devices and veterinary drugs, as well as R&D outsourcing companies to submit their projects. Proposals with the potential of being commercialized are a must for obtaining the fund support. (Click here for more - Chinese Language)
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.